PRINCETON, N.J., June 6 /PRNewswire-FirstCall/ -- Medarex, Inc.
(Nasdaq: MEDX) announced today that it is scheduled to present at the 28th
Annual Goldman Sachs Global Healthcare Conference at 11:05 AM Eastern Time
on Tuesday, June 12, 2007. The conference is being held at The Ritz Carlton
in Laguna Nigel, California. Medarex's presentation will be webcast live
and will be available for replay through the Webcasts page in the Investor
Relations section of the Medarex website via the Internet at
http://www.medarex.com.
Medarex is a biopharmaceutical company focused on the discovery,
development and potential commercialization of fully human antibody-based
therapeutics to treat life-threatening and debilitating diseases, including
cancer, inflammation, autoimmune disorders and infectious diseases. Medarex
applies its UltiMAb(R) technology and product development and clinical
manufacturing experience to generate, support and potentially commercialize
a broad range of fully human antibody product candidates for itself and its
partners. More than 30 of these therapeutic product candidates derived from
Medarex technology are in human clinical testing or have had INDs submitted
for such trials, with six of the most advanced product candidates currently
in Phase III clinical trials. Medarex is committed to building value by
developing a diverse pipeline of antibody products to address the world's
unmet healthcare needs. For more information about Medarex, visit its
website at http://www.medarex.com.
Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks
of Medarex, Inc. All rights are reserved.
SOURCE Medarex, Inc.
 back to top
Related links:
http://www.medarex.com
http://www.prnewswire.com/comp/108265.html/
CONTACT:
Investor Relations, Laura S. Choi, x2216; or
Media, Jean Mantuano, Corporate Communications, x2221, both for
Medarex, Inc., +1-609-430- 2880
|
